Nasopharyngeal Diseases  >>  Onureg (azacitidine oral)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Onureg (azacitidine oral) / BMS
NCT02269943 / 2014-001745-25: Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Completed
2
36
Canada, US, Europe, RoW
CC-486, oral azacitidine
Celgene
Nasopharyngeal Neoplasms
04/17
04/17

Download Options